Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.
Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.
Vertex (Nasdaq: VRTX) will report first quarter 2026 financial results on Monday, May 4, 2026 after market close, followed by a conference call and webcast at 4:30 p.m. ET.
Participants may join by phone or via the live webcast on the company website in the Investors section; an archived webcast will be available afterward.
Vertex (NASDAQ: VRTX) announced U.S. FDA label expansions for ALYFTREK and TRIKAFTA, extending ALYFTREK to people with CF ages 6+ and TRIKAFTA to ages 2+ when variants are responsive or produce CFTR protein. The expansions cite responses for 564 variants (ALYFTREK) and 521 variants (TRIKAFTA), adding ~800 eligible U.S. patients and bringing coverage to ~95% of people with CF in the U.S.
The labels include prominent safety guidance on drug-induced liver injury, hypersensitivity, intracranial hypertension, neuropsychiatric events, and recommended monitoring schedules.
Vertex (Nasdaq: VRTX) reported positive Week 36 interim Phase 3 RAINIER results for povetacicept in adults with IgA nephropathy (IgAN). The trial met its primary and two alpha-controlled secondary endpoints with statistically significant reductions: UPCR -49.8% vs placebo (P<0.0001), Gd-IgA1 -79.3% vs placebo (P<0.0001), and hematuria resolution +61.7% vs placebo (P<0.0001).
Povetacicept was generally safe and well tolerated, with no deaths or opportunistic infections reported. Vertex will complete its BLA submission by end of March and is pursuing potential FDA accelerated approval with a priority review voucher.
Vertex (Nasdaq: VRTX) will participate in two investor conferences in March 2026. Management will join fireside chats at the Leerink Global Healthcare Conference on March 10, 2026 at 10:00 a.m. ET and the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 11:30 a.m. ET.
Speakers include Charlie Wagner and Duncan McKechnie at Leerink, and Susie Lisa and Miroslava Minkova at Barclays.
Vertex (Nasdaq: VRTX) announced Phase 4 data showing JOURNAVX (suzetrigine) enabled opioid-free recovery in plastic surgical patients. In a 99-patient, open-label study, 90.9% were opioid free through treatment (up to 14 days) and 90.7% rated effectiveness as excellent, very good, or good (95% CI: 83.1%, 95.7%). No serious adverse events related to JOURNAVX were reported. Data accepted for oral presentation at AAPM PainConnect 2026 on March 6, 2026.
Vertex (NASDAQ: VRTX) management will participate in TD Cowen’s 46th Annual Health Care Conference on March 3, 2026. CEO Reshma Kewalramani will appear in a fireside chat at 9:10 a.m. ET. A live webcast and archived replay will be available in the Investors > News and Events section.
Vertex (NASDAQ: VRTX) reported strong commercial results and guidance on February 12, 2026. Full year 2025 total revenue was $12.0 billion (+9% year-over-year) and Q4 2025 revenue was $3.19 billion (+10% year-over-year). GAAP net income was $4.0 billion and non-GAAP net income was $4.7 billion. Cash and marketable securities totaled $12.3 billion at year-end.
Vertex provided 2026 guidance of $12.95–$13.1 billion total revenue and at least $0.5 billion from non-CF products, with combined GAAP R&D, AIPR&D and SG&A expense guidance of $6.3–$6.45 billion.
WuXi Biologics and Vertex (VRTX) signed a license and research service agreement dated Feb 2, 2026, covering an innovative trispecific T‑cell Engager (TCE) for B‑cell mediated autoimmune diseases.
Vertex receives exclusive global development and commercialization rights at the preclinical stage; WuXi Biologics will receive an upfront payment, potential development/regulatory/sales milestones and royalties, and will provide contract R&D services on next‑generation TCEs.
Satellos (GBIO) appointed Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs on January 29, 2026.
Ms. Paone joins from Generation Bio where she served as Chief Operating Officer and previously led regulatory strategy at Vertex, including work on Kalydeco and Orkambi. Satellos says her hire supports advancement of two SAT-3247 clinical studies in adult and pediatric DMD populations.
Vertex (NASDAQ: VRTX) will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 after market close. The company will host a conference call and webcast at 4:30 p.m. ET.
Dial-in numbers: (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call.” The live webcast will be available in the Investors section of Vertex's website and an archived webcast will be posted. Participants are recommended to register at least 15 minutes before the webcast to ensure timely connection.